Sarah Cannon Research Institute
Marcy Vallone has a strong background in the pharmaceutical and clinical research industry. Marcy began their career at Rigel Pharmaceuticals in 1999 as a Senior Research Associate. Marcy then moved on to Proteolix, Inc in 2004 as a Senior Clinical Research Associate. In 2007, they became a Clinical Scientist at Proteolix and later joined Onyx Pharmaceuticals in 2009 as a Clinical Research Scientist. From 2011 to 2015, Marcy served as the Sr. Director of Clinical Operations at SCRI, Development Innovations. Most recently, they have been working at the Sarah Cannon Research Institute as the Vice President of Strategic Development since 2015.
Marcy Vallone attended Washington State University from 1993 to 1997, where they obtained a Bachelor of Science (B.S.) degree in Microbiology.
Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. In 2022, SCRI formed a joint venture with former US Oncology Research to enhance clinical trial access and availability across the country. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted nearly 700 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. The combined research network brings together physicians who are actively accruing patients to clinical trials at more than 250 locations in 26 states across the US.